Principal Investigator

RESEARCH

Chronic myeloid leukemia can be treated successfully by targeted therapy with tyrosine kinase inhibitors. However resistance to TKIs occurs in 10% of patients in chronic phase and 80% patients in the acute phase of blast crisis. In India patients report to clinic with advance disease. Moreover, age at onset is a decade earlier than in the western world, thus patient is on TKIs for longer period. Both of these increase the probability  of developing  resistance to TKIs. We aim to generate molecular profiles of CD34+ cells isolated from peripheral blood of  TKI-sensitive and –resistant chronic myeloid leukemia patients  in chronic as well as acute phase.  Multi-omics approach has been applied to understand and integrate alterations in different macromolecules. This would help to understand the molecular basis of resistance to tyrosine kinase inhibitors in CML.